Effects of deutetrabenazine: A Synthesis of Findings from 26 Studies

  1. Home
  2. Effects of deutetrabenazine
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of deutetrabenazine: A Synthesis of Findings from 26 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of deutetrabenazine: A Synthesis of Findings from 26 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Deutetrabenazine has been shown to be effective in treating chorea associated with Huntington's disease (HD) and tardive dyskinesia (TD) in multiple studies. 5 , 1 Deutetrabenazine is a deuterated form of tetrabenazine, a VMAT2 inhibitor, which means it blocks the release of dopamine and other neurotransmitters from nerve cells. 5 Deutetrabenazine has a longer half-life than tetrabenazine, which means it can be taken less frequently. 5 In a Phase III clinical trial (First-HD), deutetrabenazine was significantly more effective than placebo at controlling chorea in HD patients. 5 In a separate Phase III trial (AIM-TD), deutetrabenazine was shown to significantly reduce involuntary movements associated with tardive dyskinesia. 1 Additionally, deutetrabenazine has been found to be well-tolerated and generally safe. 5

Benefits and Risks

Benefits Summary

Deutetrabenazine has been shown to be an effective treatment for chorea associated with Huntington's disease and tardive dyskinesia. 5 , 1 Deutetrabenazine offers a longer duration of action compared to tetrabenazine, resulting in less frequent dosing. 5 Additionally, deutetrabenazine has a favorable safety profile and is well-tolerated. 5

Risk Summary

Deutetrabenazine, like any medication, carries the potential for side effects. 5 The most commonly reported side effect of deutetrabenazine is somnolence (sleepiness). 5 Deutetrabenazine should be avoided in individuals with hepatic impairment. 25 Caution is advised when deutetrabenazine is used with CYP2D6 inhibitors. 25 Deutetrabenazine should be avoided during pregnancy and breastfeeding. 25

Comparison of Studies

Similarities

Multiple studies consistently show that deutetrabenazine is effective in treating chorea associated with Huntington's disease and tardive dyskinesia. 5 , 1 Furthermore, across studies, deutetrabenazine has been demonstrated to be well-tolerated and have a generally favorable safety profile compared to tetrabenazine. 5

Differences

In a study comparing deutetrabenazine and valbenazine, no significant difference was found in their effectiveness. 19 However, the study was an indirect treatment comparison, meaning that the two drugs were not directly compared in the same study.

Consistency and Discrepancies

Overall, the research consistently demonstrates deutetrabenazine's effectiveness in treating chorea and tardive dyskinesia. 5 , 1 However, the lack of direct head-to-head comparison studies between deutetrabenazine and valbenazine limits our ability to definitively conclude whether one is superior to the other. 19

Real-World Application Considerations

Deutetrabenazine, although effective, is not a cure for Huntington's disease or tardive dyskinesia. 5 It's important to remember that it's a medication with potential side effects and should be used under the guidance of a healthcare professional. It's crucial to discuss the risks and benefits with your doctor to determine if deutetrabenazine is the right treatment option for you.

Limitations of Current Research

Further research is required to fully understand the long-term effects and safety of deutetrabenazine. 5 Additionally, more direct comparative studies are needed to conclusively determine the optimal treatment approach for patients with chorea and tardive dyskinesia, taking into account factors like individual patient characteristics and symptom severity.

Future Research Directions

Future research should focus on long-term safety and effectiveness studies of deutetrabenazine, as well as head-to-head comparisons with other available therapies, such as valbenazine. Additionally, research should explore the potential of deutetrabenazine to treat other hyperkinetic movement disorders, such as Tourette syndrome. 15

Conclusion

Deutetrabenazine is an effective treatment for chorea associated with Huntington's disease and tardive dyskinesia. 5 , 1 It offers a longer half-life than tetrabenazine, resulting in less frequent dosing, and has a generally favorable safety profile. 5 However, it is important to be aware of potential side effects and to discuss the risks and benefits with your healthcare provider before starting deutetrabenazine treatment. Further research is needed to understand the long-term implications of deutetrabenazine, including its effectiveness compared to other available therapies.

Literature analysis of 26 papers
Positive Content
24
Neutral Content
1
Negative Content
1
Article Type
4
0
0
14
25
1.

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Author: AndersonKaren E, StamlerDavid, DavisMat D, FactorStewart A, HauserRobert A, IsojärviJouko, JarskogL Fredrik, Jimenez-ShahedJoohi, KumarRajeev, McEvoyJoseph P, OchudloStanislaw, OndoWilliam G, FernandezHubert H

Tardive dyskinesia treatment

This study aimed to assess the efficacy, safety, and tolerability of deutetrabenazine, a novel vesicular monoamine transporter-2 inhibitor, for the treatment of tardive dyskinesia. The study found that deutetrabenazine was effective in reducing tardive dyskinesia symptoms and was generally well-tolerated.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Deuterium Tetrabenazine for Tardive Dyskinesia.

Author: CummingsMichael A, ProctorGeorge J, StahlStephen M

TD treatment

Deutetrabenazine (Austedo®) is effective in treating tardive dyskinesia, a movement disorder caused by antipsychotic medication. It offers less frequent dosing and a better short-term adverse effect profile than tetrabenazine.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Current treatment of tardive dyskinesia.

Author: MargoliusAdam, FernandezHubert H

TD treatment

Tardive dyskinesia (TD) is a common, iatrogenic movement disorder affecting many individuals treated with dopamine-receptor blocking agents (DRBAs). This article reviews various treatments of TD, including manipulation of the offending agent, VMAT2 inhibitors, other non-VMAT2-inhibiting medications, and non-pharmacological approaches.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.

Author: ClaassenDaniel O, PhilbinMichael, CarrollBenjamin

TD treatment
chorea treatment
improved pharmacokinetics
similar to placebo

Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is effective in treating Huntington's disease (HD)-associated chorea and tardive dyskinesia (TD). Clinical trials show consistent efficacy and a safety profile similar to placebo. Deutetrabenazine is likely to play a key role in the treatment of these movement disorders.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.

Author: FernandezHubert H, StamlerDavid, DavisMat D, FactorStewart A, HauserRobert A, Jimenez-ShahedJoohi, OndoWilliam G, JarskogL Fredrik, WoodsScott W, BegaDanny, LeDouxMark S, ShprecherDavid R, AndersonKaren E

Safe and effective
Tardive dyskinesia treatment

Long-term treatment with deutetrabenazine was efficacious, safe, and well tolerated in patients with tardive dyskinesia.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Palladium-catalyzed directed synthesis of <i>ortho</i>-deuterated phenylacetic acid and analogues.

Author: MannaPriyadarshi, KunduMrinalkanti, RoyAshis, AdhikariSusanta

Deuterium-labeled compound synthesis

This study describes a new method for incorporating deuterium into organic compounds, specifically phenylacetic acid derivatives. The method uses a palladium catalyst and a directing group to achieve high levels of deuterium incorporation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Genetics of tardive dyskinesia: Promising leads and ways forward.

Author: ZaiClement C, MaesMiriam S, TiwariArun K, ZaiGwyneth C, RemingtonGary, KennedyJames L

TD treatment

Tardive dyskinesia (TD) is a serious movement disorder that can result from long-term use of dopamine receptor blocking medications. Genetic factors have been identified that may contribute to TD, including genes involved in dopamine signaling and other pathways. This review discusses the potential role of these genes in TD, particularly in light of the recent approvals of valbenazine and deutetrabenazine, VMAT2 inhibitors, for the treatment of TD.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.

Author: FrankSamuel, TestaClaudia, EdmondsonMary C, GoldsteinJody, KaysonElise, LeavittBlair R, OakesDavid, O'NeillChristine, VaughanChristina, WhaleyJacquelyn, GrossNicholas, GordonMark Forrest, SavolaJuha-Matti,

Reduced chorea
Akathisia
Anxiety
Depression
Insomnia
Parkinsonism
Somnolence
Suicidality

Deutetrabenazine was safe and well-tolerated for the long-term treatment of Huntington disease. Chorea reduction persisted over time, and there was no unexpected worsening of chorea upon treatment cessation.

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Benign Presentation Following Massive Deutetrabenazine Overdose.

Author: ObadeyiOluseyi, PaxtonJames H, KouyoumjianSarkis

Improved chorea symptoms
Overdose

Deutetrabenazine is a new drug for the treatment of tardive dyskinesia (TD). This case report describes a patient who overdosed on deutetrabenazine and experienced limited side effects, suggesting a good safety profile for this drug.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

12.

Real-World Experience With VMAT2 Inhibitors.

Author: NiemannNicki, JankovicJoseph

Hyperkinetic movement disorders treatment
Insurance and regulatory issues
Physician inexperience
Side effects

VMAT2 inhibitors like tetrabenazine, deutetrabenazine, and valbenazine are used to treat hyperkinetic movement disorders. However, access and adherence can be limited by insurance, physician experience, efficacy, and side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Pragmatic Clinical TrialA trial conducted in a real-world clinical setting. It evaluates the effectiveness of interventions in everyday healthcare environments.

Language : English

13.

Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.

Author: HeoYoung-A, ScottLesley J

Control chorea
Improved tolerability
Somnolence

Deutetrabenazine is a new medication for controlling chorea in Huntington's disease. It has a similar safety profile to placebo and is potentially better tolerated than tetrabenazine, while maintaining its efficacy. Further research is needed to confirm its long-term safety and efficacy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

Valbenazine for the treatment of tardive dyskinesia.

Author: MüllerThomas

Tardive dyskinesia treatment
Motor side effects
Psychopathological side effects

Valbenazine, a selective inhibitor of vesicular monoamine transporter 2, is a promising treatment option for tardive dyskinesia (TD). Compared to tetrabenazine, valbenazine may have fewer side effects and a more favorable once-daily dosing regimen.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.

Author: FernandezHubert H, FactorStewart A, HauserRobert A, Jimenez-ShahedJoohi, OndoWilliam G, JarskogL Fredrik, MeltzerHerbert Y, WoodsScott W, BegaDanny, LeDouxMark S, ShprecherDavid R, DavisCharles, DavisMat D, StamlerDavid, AndersonKaren E

Reduced abnormal movements
Well tolerated

Deutetrabenazine was well tolerated and significantly reduced abnormal movements in patients with tardive dyskinesia (TD). Patients on deutetrabenazine had a greater reduction in Abnormal Involuntary Movement Scale scores compared to placebo.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

17.

VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.

Author: KimAnne P, BakerDanial E, LevienTerri L

Reduced TD symptoms
Adverse effects

Valbenazine and deutetrabenazine are the first FDA-approved treatments for tardive dyskinesia (TD). Further data from postmarketing studies will be needed to verify that valbenazine's adverse effect profile is different from the profiles of tetrabenazine and deutetrabenazine.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.

Author: MeyerJonathan M

Tardive dyskinesia treatment

Despite the widespread use of atypical antipsychotics, tardive dyskinesia (TD) remains a significant challenge due to its persistent symptoms and limited treatment options. This review explores the current understanding of TD, including its pathophysiology, risk factors, and treatment strategies. It highlights the potential benefits of new agents, deuterated tetrabenazine and valbenazine, for the management of TD.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

19.

Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.

Author: AggarwalSaurabh, SerbinMichael, YonanChuck

Valbenazine more effective

Valbenazine was generally favorable over deutetrabenazine for treatment of tardive dyskinesia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

New generation VMAT2 inhibitors induced parkinsonism.

Author: VasireddyRani Priyanka, SokolaBrent, GuduruZain

Drug-induced parkinsonism
Unmask Parkinson's

Valbenazine and deutetrabenazine, VMAT-2 inhibitors, can cause drug-induced parkinsonism, unmasking underlying Parkinson's disease. Potential side effects of these drugs include muscle stiffness, tremors, and difficulty moving.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer.

Author: BeleteTafere Mulaw

Improved efficacy
Improved safety
Increased half-life
Reduced dose

Deuterium incorporation is a promising approach to improve drug safety and efficacy by reducing metabolism and increasing half-life. This review discusses the deuterium kinetic isotope effect on drug metabolism and the development of deuterated anticancer drugs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

25.

Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.

Author: CitromeLeslie

TD treatment

Valbenazine and deutetrabenazine are two VMAT2 inhibitors approved for treating tardive dyskinesia, an iatrogenic movement disorder caused by dopamine receptor blockers.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

26.

Deutetrabenazine for the treatment of Huntington's chorea.

Author: BashirHassaan, JankovicJoseph

HD chorea treatment
Lower adverse effects

This review summarizes the pharmacological properties, clinical evidence of efficacy and tolerability of deutetrabenazine, a deuterated drug, for treating chorea associated with Huntington's disease (HD). Deutetrabenazine has shown promise as an effective treatment with a lower risk of adverse effects compared to tetrabenazine.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.